Altimmune, Inc. (NASDAQ:ALT) Q4 2023 Earnings Call Transcript

We have other options to look at that as well that we can detail in the future. In terms of the MASH program, I think we’ve always had confidence in our ability to differentiate against the other drugs in MASH. Everyone has mentioned the anti-fibrotic potential of pemvidutide. We think that based on the glucagon content of the molecule, we’re going to get even better effects. You’d be able to demonstrate that potency by getting statistical significance at 24 weeks of treatment rather than 48 weeks of treatment. The anti-fibrotic data that Scot described on the call also increases our confidence that we’re going to hit the fibrosis endpoint because we’re not only moving fibrosis by reducing liver fat or having a direct anti-fibrotic effect, which is very important as well.

Vipin Garg: Yes. Just only one thing I would add to that, that in terms of looking at the Phase III plans, I mean, as you know, for Phase III, we’re going to need thousands of patients, particularly for a safety database. So that gives us the opportunity to actually have multiple patient population that we can test, we can study under the Phase III program, particularly given the differentiation of pemvidutide. For instance, we might be able to have a subpopulation looking at high serum lipids and show that benefit and try to get that on the label. So that’s — those are the kind of discussions and considerations that we are going through in terms of how we designed the Phase III program.

Operator: This concludes the question-and-answer session. I’d like to turn the call back over to Vipin Garg for the closing remarks.

Vipin Garg: Thank you, everyone, for participating today. We appreciate this opportunity to share our results and outlook with you, and thank you for your continued interest. Have a nice day.

Operator: Thank you for your participation. This does conclude the program. You may now disconnect. Good day.